JAMA

Alimentiv Inc. Announces New Scientific Advisors Leading Research In GI-Related Therapeutics

Retrieved on: 
Friday, October 13, 2023

LONDON, ON, Oct. 13, 2023 /PRNewswire/ -- Alimentiv Inc. ("Alimentiv"), a leading Contract Research Organization focused on GI-related therapeutics, is pleased to announce the addition of new scientific advisors to its scientific advisory board.

Key Points: 
  • LONDON, ON, Oct. 13, 2023 /PRNewswire/ -- Alimentiv Inc. ("Alimentiv"), a leading Contract Research Organization focused on GI-related therapeutics, is pleased to announce the addition of new scientific advisors to its scientific advisory board.
  • The advisors are internationally recognized experts in designing and conducting clinical research in Inflammatory Bowel Disease.
  • Their contributions to the field have been essential in progressing the development of novel therapies in IBD and improving patient outcomes.
  • He holds the Crohn's Colitis Canada Endowed Research Chair in Inflammatory Bowel Disease and is an executive member of the IOIBD.

Highmark Health and Spring Health Collaborate to Launch My Highmark's Mental Well-Being Powered by Spring Health

Retrieved on: 
Monday, October 9, 2023

LAS VEGAS, Oct. 9, 2023 /PRNewswire/ -- Highmark Health and Spring Health today announced their collaboration to expand the number of access points to behavioral health care by 40 percent for Highmark insurance members, including children and teens. Highmark's Mental Well-Being powered by Spring Health will offer multiple levels of support: digital capabilities for daily wellness, one-on-one care navigation, deeper clinical care through in-person or virtual therapy, medication management, and 24/7 crisis support.

Key Points: 
  • "Together, Highmark Health and Spring Health are advancing the future state of mental and behavioral health," said Anil Singh, MD, MPH, FCC, senior vice president, executive medical director of population and curated health, Highmark Health.
  • Mental Well-Being is powered by Spring Health, the most comprehensive global mental health solution for employers and health plans, and provides members with access to therapy and medication management appointments in an average of three days or less.
  • "Spring Health's precision technology is changing the mental health paradigm," said Adam Chekroud, PhD, president and co-founder, Spring Health.
  • Mental Well-Being powered by Spring Health will be available to health plan members through the My Highmark member platform.

HiLabs' AI engine processes clinical data 100x faster than humans, unlocks unused data

Retrieved on: 
Thursday, October 5, 2023

BETHESDA, Md., Oct. 5, 2023 /PRNewswire/ -- HiLabs' AI-powered engine, MCheck, proves capable of ingesting, indexing, and summarizing clinical data 100 times faster than humans, building on the engine's capabilities in provider data recently published in JAMA.

Key Points: 
  • BETHESDA, Md., Oct. 5, 2023 /PRNewswire/ -- HiLabs' AI-powered engine, MCheck, proves capable of ingesting, indexing, and summarizing clinical data 100 times faster than humans, building on the engine's capabilities in provider data recently published in JAMA.
  • Cleans clinical and supplemental data 100x faster than human operators.
  • Clinical data contains enormous potential to uncover patient insights and improve health on a population level.
  • HiLabs' AI engine, MCheck, successfully completed the complex task of standardizing such clinical and supplemental data sources for a national health plan at a rate 100 times faster than their current labor-intensive operations.

Ionis shares significant business and pipeline progress at Innovation Day, highlighting strength of capabilities from research and technology through commercialization

Retrieved on: 
Wednesday, October 4, 2023

Presentations from Ionis leaders and external physicians will highlight Ionis' comprehensive integrated research, development, and commercialization capabilities, along with key pipeline and technology highlights.

Key Points: 
  • Presentations from Ionis leaders and external physicians will highlight Ionis' comprehensive integrated research, development, and commercialization capabilities, along with key pipeline and technology highlights.
  • "Our powerful and prolific research and development engine has discovered groundbreaking medicines for people with devastating diseases.
  • We have matched this engine with a talented commercial organization poised to deliver a steady flow of wholly owned medicines to patients.
  • The event will take place at the Westin New York Grand Central from 8:00 a.m. to 3:00 p.m. Eastern Time and will also be webcast.

HUTCHMED Announces Submission of New Drug Application for Fruquintinib for Previously Treated Metastatic Colorectal Cancer in Japan

Retrieved on: 
Friday, September 29, 2023

Fruquintinib is a selective inhibitor of vascular endothelial growth factor receptors (“VEGFR”) -1, -2 and -3, which play a pivotal role in blocking tumor angiogenesis.

Key Points: 
  • Fruquintinib is a selective inhibitor of vascular endothelial growth factor receptors (“VEGFR”) -1, -2 and -3, which play a pivotal role in blocking tumor angiogenesis.
  • The FRESCO-2 and FRESCO clinical trials compared fruquintinib plus best supportive care (“BSC”) with placebo plus BSC in patients with previously treated metastatic CRC.
  • The U.S. Food and Drug Administration (“FDA”) granted Priority Review and assigned a Prescription Drug User Fee Act (PDUFA) goal date of November 30, 2023.
  • A Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) was validated and accepted for regulatory review in June 2023.

HealthTap Launches AI-Powered Patient Interviews Using GPT-4 to Enhance Telemedicine Visits

Retrieved on: 
Wednesday, September 27, 2023

SUNNYVALE, Calif., Sept. 27, 2023 /PRNewswire/ -- HealthTap, a leading virtual healthcare provider delivering quality, affordable primary care across the U.S., today launched a new version of its Dr.A.I.™ feature, a pre-appointment patient interview experience powered GPT-4. The most advanced ChatGPT system from OpenAI, GPT-4 is an artificial intelligence language model capable of human-like conversation. Dr.A.I.™.

Key Points: 
  • The most advanced ChatGPT system from OpenAI, GPT-4 is an artificial intelligence language model capable of human-like conversation.
  • Patient intake interviews powered by GPT-4 means HealthTap doctors can spend more time providing personalized care.
  • "The patient information provided to HealthTap doctors by Dr.A.I.™ lets us be more precise and informed during the doctor visit, said Dr. Geoffrey Rutledge, HealthTap's chief medical officer.
  • "The world wonders how we got along before telemedicine; soon we'll wonder what we did before Dr.A.I.™."

Fight Colorectal Cancer Hosts Congressional Black Caucus Panel to Tackle Disparities and Drive Progress

Retrieved on: 
Thursday, September 21, 2023

Recognizing the urgency of this issue, Fight Colorectal Cancer (Fight CRC) , the nation's largest colorectal cancer (CRC) advocacy organization, is set to host their inaugural panel at The Congressional Black Caucus Foundation's Annual Legislative Conference (ALC) .

Key Points: 
  • Recognizing the urgency of this issue, Fight Colorectal Cancer (Fight CRC) , the nation's largest colorectal cancer (CRC) advocacy organization, is set to host their inaugural panel at The Congressional Black Caucus Foundation's Annual Legislative Conference (ALC) .
  • Scheduled for September 22, 9-10 am EST, this panel will convene experts, advocates, and policymakers to address the critical disparities in colorectal cancer outcomes among Black Americans.
  • Fight CRC's panel titled 'A Call to Action: Fighting Colorectal Cancer in the Black Community' is co-hosted by Members of Congress, including Representative Donald Payne Jr. (D-NJ) and Representative Nikema Williams (D-GA).
  • Colorectal cancer has a devastating impact on the Black community, with Black Americans being 20% more likely to receive a diagnosis of colorectal cancer compared to their white counterparts.

Ohio Locking Vial Program Designated Best Practice for MAT/MOUD Treatment by Leading Public Health Organization

Retrieved on: 
Tuesday, September 19, 2023

The intervention was also selected for a "Best of the Best Presentation" at the NACCHO 360 annual conference.

Key Points: 
  • The intervention was also selected for a "Best of the Best Presentation" at the NACCHO 360 annual conference.
  • The intervention indicated that the use of locking prescription vials (LPVs) reduced one of the common barriers for patient participation in MOUD programs, which include accessibility, stigma, and medication safety.
  • "The intent of the intervention was to see if locking vials could be used as a tool to decrease diversion and increase patient safety and confidence.
  • "As a prescriber, I feel much more confident using the locking prescription vial for the safety of young children and families in my community.

Mineralys Therapeutics Announces JAMA Publication of Full Target-HTN Phase 2 Trial Results for Lorundrostat in Uncontrolled and Treatment-Resistant Hypertension

Retrieved on: 
Sunday, September 10, 2023

RADNOR, Pa., Sept. 10, 2023 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension, chronic kidney disease and other diseases driven by abnormally elevated aldosterone, today announced that full results from the Target-HTN Phase 2 trial of lorundrostat, a highly selective aldosterone synthase inhibitor, in individuals with uncontrolled hypertension (uHTN) and treatment-resistant hypertension (rHTN) were published in the Journal of the American Medical Association (JAMA).

Key Points: 
  • “Despite the multitude of currently available treatments, half of all patients treated for hypertension are not able to reach their blood pressure goal.
  • “We are gratified that JAMA chose to highlight our Target-HTN Phase 2 trial results.
  • "We believe this trial confirms the link between obesity, excess aldosterone production and hypertension.
  • The Target-HTN (NCT05001945) Phase 2 proof-of-concept trial was a randomized, double-blind, placebo-controlled, dose-ranging, multicenter trial conducted in the U.S.

Mineralys Therapeutics Presents Target-HTN Phase 2 Trial Results in Late-Breaking Science Session at 2023 AHA Hypertension Scientific Sessions

Retrieved on: 
Sunday, September 10, 2023

RADNOR, Pa., Sept. 10, 2023 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension, chronic kidney disease and other diseases driven by abnormally elevated aldosterone, today presented final results from the Target-HTN Phase 2 trial of lorundrostat, a highly selective aldosterone synthase inhibitor, in individuals with uncontrolled hypertension (uHTN) and resistant hypertension (rHTN). The data were presented during a late-breaking science session at the 2023 American Heart Association (AHA) Hypertension Scientific Sessions, which is being held in Boston from September 7–10, and simultaneously published in the Journal of the American Medical Association (JAMA).

Key Points: 
  • The data were presented during a late-breaking science session at the 2023 American Heart Association (AHA) Hypertension Scientific Sessions, which is being held in Boston from September 7–10, and simultaneously published in the Journal of the American Medical Association (JAMA).
  • The reduction in BP was particularly evident among participants with hypertension and concomitant obesity.
  • “The final results from our Target-HTN trial demonstrate lorundrostat had a robust, double-digit reduction in systolic blood pressure with a well-tolerated profile in the intention-to-treat population of individuals with uncontrolled hypertension and resistant hypertension.
  • The presentation at the 2023 AHA Hypertension Scientific Sessions, titled, “Aldosterone Synthase Inhibition with Lorundrostat for Uncontrolled Hypertension: The Target‐HTN Phase 2 Randomized Clinical Trial,” can be accessed on the publications page of the Mineralys corporate website.